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Abstract
Due to the rapid emergence of resistance to classical antibiotics, novel antimicrobial com-
pounds are needed. It is desirable to selectively kill pathogenic bacteria without targeting
other beneficial bacteria in order to prevent the negative clinical consequences caused by
many broad-spectrum antibiotics as well as reducing the development of antibiotic resis-
tance. Antimicrobial peptides (AMPs) represent an alternative to classical antibiotics and it
has been previously demonstrated that Cap18 has high antimicrobial activity against a
broad range of bacterial species. In this study we report the design of a positional scanning
library consisting of 696 Cap18 derivatives and the subsequent screening for antimicrobial
activity against Y. ruckeri, A. salmonicida, S. Typhimurium and L. lactis as well as for hemo-
lytic activity measuring the hemoglobin release of horse erythrocytes. We show that the
hydrophobic face of Cap18, in particular I13, L17 and I24, is essential for its antimicrobial
activity against S. Typhimurium, Y. ruckeri, A. salmonicida, E. coli, P. aeruginosa, L. lactis,
L. monocytogenes and E. faecalis. In particular, Cap18 derivatives harboring a I13D, L17D,
L17P, I24D or I24N substitution lost their antimicrobial activity against any of the tested bac-
terial strains. In addition, we were able to generate species-specific Cap18 derivatives by
particular amino acid substitutions either in the hydrophobic face at positions L6, L17, I20,
and I27, or in the hydrophilic face at positions K16 and K18. Finally, our data showed the
proline residue at position 29 to be essential for the inherent low hemolytic activity of Cap18
and that substitution of the residues K16, K23, or G21 by any hydrophobic residues
enhances the hemolytic activity. This study demonstrates the potential of generating spe-
cies-specific AMPs for the selective elimination of bacterial pathogens.
Introduction
In recent years, the widespread use of antibiotics has contributed to the selection for microor-
ganisms with antibiotic resistance and to the selection for transmission of antibiotic resistance
mechanisms between quite distantly related organisms. The number of resistant superbugs is
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increasing and new anti-infective solutions are urgently needed. However, the time for devel-
opment of a new antimicrobial drug is quite lengthy compared to the current dissemination of
novel antibiotic resistance mechanisms among commensal and pathogenic microorganisms
[1–4]. We are therefore in a state of extreme vulnerability with a risk for reappearance of epi-
demics of infectious diseases.
The use of traditional antibiotics not only select for resistance in a broad range of patho-
gens, but also disturbs and alters the natural flora, which plays an important role in human
and animal health [5–8]. This is one reason behind major health problems/antibiotics-associ-
ated infections such as Clostridium difficile infections in humans and animals resulting in
severe and sometimes fatal enteric diseases [9]. More recent studies have shown that tradi-
tional antibiotic treatment can perhaps have lifelong negative consequences due to the perma-
nent disturbance of the microbiota. Therefore, much of the current research in infection
therapy is aiming at identifying alternatives which are safer, more specific for a given bacteria
target to reduce or eliminate such deleterious side effects on the microbiota and are more sus-
tainable than the traditional antibiotics. New and non-conventional antimicrobials with spe-
cies-specific killing capability are needed to prevent posttreatment complications and to
overcome a future “post-antibiotic era”.
Antimicrobial peptides (AMPs) captured attention and might present an attractive alterna-
tive to classical antibiotics. AMPs have been found in all kingdoms of life and are part of the
innate immunity and represent the first line of defense in an infection [10,11]. Despite their
diversity in origin and sequence, they generally have a substantial proportion of hydrophobic
amino acids (=>30%), an overall positive charge (+2 to +11) and are relatively short consist-
ing of 10–50 amino acids [12]. Based on these properties, AMPs are able to fold into amphi-
philic three-dimensional structures and are often based on their secondary structure
categorized into α-helical, β-sheet or peptides with extended/random coil structure. Most of
the so far characterized AMPs belong to the family of the α-helical or β-sheet peptides [13,14].
It is widely accepted that the bacterial membrane is the key component for the antimicro-
bial activity of AMPs. Based on a considerable amount of in vitro data showing the disruption
of lipid bilayers by AMPs, it has been suggested that the bactericidal effect of AMPs is mainly
due the formation of pores in the cytoplasmic membrane disrupting the physical integrity of
bacterial membrane which finally leads to cell death [12,14,15]. However, the exact mechanism
of pore formation in bacterial membrane is less certain. It is widely believed that electrostatic
forces between the positively charged amino acids of the AMPs and the negatively charged
bacterial surface are the initial step and critical determinants for interactions between AMPs
and the bacterial membrane. In addition to the negatively charged phospholipids such as phos-
phatidylglycerol, cardiolipin and phosphatidylserine present in the bacterial cytoplasmic mem-
brane, lipopolysaccharides (LPS) in the outer membrane of Gram-negative bacteria and
teichoic acids in the peptidoglycan layer of Gram-positive bacteria are contributing to the
overall negative charge of the bacterial cell envelope [16]. The positively charged AMP is
expected to accumulate on the surface of the membrane and upon reaching a certain threshold
the AMP might self-assemble and incorporate into the membrane by creating a pore. Several
models for pore formation of AMPs have been suggested including the barrel-stave model, the
carpet mechanism and the toroidal pore model [17]. Besides membrane dysfunction and dis-
ruption caused by the leakage of ions and metabolites and depolarization of the transmem-
brane potential, membrane permeabilization is crucial for the translocation of certain AMPs
into the cytoplasm acting on key cellular mechanisms such as DNA, RNA and protein synthe-
sis, enzymatic activity, protein folding and cell wall synthesis [14,15].
Since the interaction of the AMP with the membrane is the key step for the mechanism of
most AMPs, discrimination between eukaryotic and prokaryotic membrane is crucial for
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potential successful drug candidate. The difference between bacterial and mammalian
membranes enables as selective action of the AMPs. In contrast to bacteria, the cytoplasmic
membrane of mammalian cells has neutral net charge consisting of mainly zwitterionic phos-
pholipids such as phosphatidylcholine, sphingomyelin and phosphatidylethanolamine [18,19].
In addition, mammalian cell membranes have a high content of cholesterol which is supposed
to reduce the antimicrobial activity of AMPs by stabilizing the membrane [10,18,20]. Despite
those fundamental differences between mammalian and bacterial membranes, many AMPs
are hemolytic and able to lyse mammalian cells. Minimizing cell toxicity, while at the same
time maximizing antimicrobial activity is a major challenge in the development of AMPs for
clinical applications.
It must be expected that AMPs during evolution have evolved towards a high general activ-
ity against multiple microorganisms. In this study, we address the issues of species specificity,
hemolytic activity and antimicrobial activity of Cap18, a α-helical peptide of the cathelicidin
family. Our previous study demonstrated that Cap18, originally isolated from rabbit neutro-
phils, has high antimicrobial activity against a broad range of pathogenic bacteria, is highly
thermostable and showed no hemolytic activity in vitro [21]. In addition, a recent study evalu-
ated a potential therapeutic effect of Cap 18 against the red mouth disease in juvenile rainbow
trout caused by Y. ruckeri either by oral administration or intraperitoneal injection. It was con-
cluded that, injection of Cap18 into juvenile rainbow trout before exposure to Y. ruckeri was
associated with lower mortality compared to non-treated fish [22]. Based on those properties,
Cap18 has the potential to act as lead peptide for further development and optimization. Here,
we report the design of a Cap18 peptide library consisting of 696 Cap18 derivatives which was
screened for antimicrobial and hemolytic activity and analyzed for species specific killing. In
particular, the Cap18 library was screened for antimicrobial activity against S. Typhimurium,
an important foodborne pathogen and Y. ruckeri and A. salmonicida, two important fish path-
ogens accounting for substantial economic losses in aquaculture. We successfully identified
Cap18 variants with changed target specificity and species-specific killing properties and
amino acid residues important for antimicrobial and hemolytic activity. Based on our results,
we show that changing one single amino acid of Cap18 can lead to changed species specificity
of Cap18.
Materials and methods
Bacterial strains and growth conditions
The strains used in this study are listed in Table 1. The Y. ruckeri strain was kindly provided by
Prof. Kurt Buchmann, University of Copenhagen, Faculty of Health and Medical Sciences,
Denmark.
All strains were grown in Mueller-Hinton-II medium, except L. monocytogenes which was
grown in BHI medium and L. lactis which was grown in MRS medium. Incubation took place
aerobically at 37˚C, except for Y. ruckeri and A. salmonicida, which were grown aerobically at
RT (20 ˚C), and L. lactis grown aerobically at 30˚C. All plates were incubated for 16–21 hours.
Antimicrobial peptides
All peptides used in this study were purchased as chemically synthesized peptides with either
crude purity for the peptide library peptides from Genscript or with high purity from Gen-
script or Peptide 2.0. The purity of each peptide was determined by the supplier by HPLC and
MS analysis. Peptide purity values are given in S1 Table. All peptides were dissolved in 100%
DMSO at a stock concentration of 10 mg/ml and stored at -20˚C.
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Antimicrobial susceptibility testing (MIC testing)
The minimum inhibitory concentrations (MICs) of the AMPs were measured in 96-well
microtiter plates according the Clinical and Laboratory Standards Institute (CLSI, formerly
National Committee for Clinical Laboratory Standards [NCCLS]) [26]. Briefly, liquid Mueller-
Hinton-II medium containing increasing concentrations of AMPs is inoculated with a defined
number of cells (approx. 105 CFUs/ml) in 96-well microtiter plates (polypropylene), whereas
each plate also includes a positive growth control and a negative control (sterile control). The
range of peptide concentrations analyzed was 0.125–64 μg/ml for the high purity peptides and
0.06–32 μg/ml for peptides of the variant library. After incubation, the MIC is determined by
the lowest concentration showing no visible growth. All plates were incubated for 16–20
hours. The MIC of the reference antibiotics was determined by the use of Sensititre panels
(Trek Diagnostic Systems Ltd, East Grinstead, UK).
Cytotoxicity assay
The cytotoxicity for each AMP was determined spectrophotometrically by measuring the
haemoglobin release from horse erythrocytes. Briefly, fresh defibrinated horse blood was
washed three times with PBS, centrifuged for 15 minutes at 1000g and resuspended at
10% (v/v) in PBS. Samples of the washed horse erythrocytes (100 μl) were transferred to a
96 well microtiter plate and mixed with 100 μl AMP solution. The final AMP concentra-
tion in the assay was (32 μg/ml). PBS was used as a negative control, and 0.2% TritonX-
100 was used as a positive control. The microtiter plates were incubated for 60 minutes at
37˚C and then centrifuged for 10 minutes at 1300g. The supernatants were transferred to
a flat-bottom 96 well polystyrene mircotiter plate and the haemoglobin release was moni-
tored by measuring the absorbance at 540 nm. The percentage of haemolysis was calcu-
lated as 100 (Asample−APBS)/(ATritonX-100 –APBS), where Asample is the experimental
absorbance of the peptide sample, APBS is the control absorbance of untreated erythro-
cytes, and ATritonX-100 is the absorbance of 0.2% TritonX-100 lysed cells.
Results
Broad antimicrobial activity of Cap18
Cap18 is highly active in particular against Gram-negative bacteria including the foodborne
pathogens Salmonella Typhimurium and Campylobacter jejuni and the fish pathogens Yersina
ruckeri and Aeromonas salmonicida, which are a major problem in fish farming (Table 2). The
antimicrobial activity of Cap18 against Y. ruckeri is similar to the well-known antibiotics
Table 1. Strains used in this study.
Strain Relevant characteristics /genotype Reference(s)
Aeromonas salmonicida ATCC33658 Type strain ATCC strain collection
Yersinia ruckeri 392/2003 [23]
Salmonella enterica serovar Typhimurium LT2 sequenced
Lactococcus lactis IL1403 [24]
Escherichia coli ATCC25922 Clinical isolate, Serotype O6, Biotype 1, reference strain ATCC strain collection
Staphylococcus aureus ATCC29213 reference strain for antimicrobial susceptibility testing ATCC strain collection
Enterococcus faecalis ATCC29212 reference strain for antimicrobial susceptibility testing ATCC strain collection
Pseudomonas aeruginosa ATCC27853 reference strain for antimicrobial susceptibility testing ATCC strain collection
Listeria monocytogenes N22-2 Isolate from fish processing industry [25]
Escherichia coli ATCC25922 Clinical isolate, Serotype O6, Biotype 1, reference strain ATCC strain collection
https://doi.org/10.1371/journal.pone.0197742.t001
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ampicillin, gentamicin and polymyxin E and even more active than nalidixic acid. However,
Cap18 is not only active against pathogenic organisms, but shows a broader range of antimi-
crobial activity including high antimicrobial activity against beneficial organisms such as Lac-
tococcus lactis (Table 2)
Design of a Cap18 positional scanning library consisting of 703 peptide
variants
In order to optimize the antimicrobial properties of Cap18 and to identify specific residues
crucial for the antimicrobial activity, a positional scanning library of Cap18 was designed (S1
Fig). By sequentially substituting each amino acid of the wild-type Cap18 peptide by all other
natural amino acids, a peptide library consisting of 703 chemically synthesized peptides was
generated. Each individual peptide of this positional scanning library harbors one single
amino acid change compared to the Cap18 wild-type peptide. The library peptides were pur-
chased from Genscript as chemically synthesized peptides with crude purity. The purity of the
individual peptides varied from 15.8% to 81% purity, whereas most of the peptides showed a
purity between 30%-60% (S1 Table). After correcting for the different purity of each peptide,
only 7 peptides were not soluble in 100% DMSO, including the peptides with the following
amino acid changes: K4F, P33K, P33N, P33S, R34C, T35V and D36F. Those peptides were dis-
carded and therefore not used for further screening. To validate the quality of the peptide
library, the MIC values were measured for the high purity Cap18 peptide (89.5% purity) and
for the library Cap18 peptide (47.5% purity) and compared (Table 2).
Antimicrobial activity screening of 696 Cap18 derivatives against Yersinia
ruckeri,Aeromonas salmonicida and Salmonella Typhimurium
The 696 Cap18 derivatives were screened for antimicrobial activity against Salmonella Typhi-
murium, Aeromonas salmonicida and Yersinia ruckeri, all important Gram-negative pathogens
either in human health or animal production. The antimicrobial activity was recorded for each
individual peptide by measuring the MIC values against all three pathogens. The screening
results are summarized (Figs 1–3). For A. salmonicida, 55.2% of all the tested peptides showed
the same antimicrobial activity as the original Cap18 (Table 3). 53 derivatives (7.6%) showed a
0.5–2 fold increase and 4 derivatives (0.4%) exhibited a 2–4 fold increase compared to the
Table 2. Antimicrobial activity of Cap18 and selected antibiotics.
Antimicrobial Activity MIC [μg/ml]
Cap18—
Pure
( 89.5%
purity)
Cap18—Library
(47.5% purity)
Ampicillin Gentamicin Nalidixic acid Polymyxin E
Yersinia ruckeri 392/2003 2–4 2 2 1–2 32 1–2
Aermononas salmonicida ATCC33658 4 2 1 1 4 2
Salmonella Typhimurium LT2 4–8 2–4 1 0.5–1 4 2
Lactococcus lactis IL1403 1–2 2–4 n.d. n.d. n.d. n.d.
Data are collected as minimal inhibitory concentrations (MICs) according to the Clinical and Laboratory Standards Institute (CLSI) and expressed in μg/ml. All MIC
determinations were carried out in triplicates for Cap18—pure and in duplicates for Cap18 –library. MIC determination for the standard antibiotics were carried out in
triplicates. n.d = not determined. MIC values are given as a single value when replicates gave identical results whereas two values are given when replicates differed by
one well. For standard antibiotics the symbol is used to indicate sensitivity to the lowest concentration for this antibiotic in the Sensititre plate.
https://doi.org/10.1371/journal.pone.0197742.t002
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original Cap18 peptide. A major loss in antimicrobial activity was measured for 25 (3.6%)
Cap18 peptides with an 8 fold decrease and 11 (1.6%) variants with a decrease of at least 16
fold compared to the original peptide (Table 3). Similar results were obtained for the screening
against Y. ruckeri (Table 3). For Y. ruckeri, 53.9% of the derivatives showed unchanged activity;
only 7 peptides had a 2–4 fold increased activity while 26 derivatives showed a major reduction
of activity of at least 16-fold. For S. Typhimurium, 82.7% of all the tested Cap18 derivatives
unchanged antimicrobial activity. 5 Cap18 derivatives with a 2–4 fold increased and 14 vari-
ants with8-fold reduced antimicrobial activity were identified (Table 3).
An intact hydrophobic face is crucial for the antimicrobial activity of
Cap18
The screening data of 696 Cap18 derivatives allowed identifying key residues of Cap18 which
are important for the antimicrobial activity specifically against A. salmonicida, Y. ruckeri or S.
Typhimurium. The analysis of the antimicrobial activity of Cap18 against A. salmonicidia
revealed that the hydrophobic residues I13, L17, I24 and L28 are important for the antimicro-
bial activity of Cap18. In particular, Cap18 derivatives with amino acids changes at position
I13 either by D, F, P or R show a major loss of activity compared to the original Cap18 peptide.
The MIC values are more than 16 times higher than the original Cap18 (Table 4). Similarly,
substituting amino acid L17 by D or P, amino acid I24 by D, E, N, Q, R and amino acid L28 by
K led to a major loss of antimicrobial activity (Table 4).
Fig 1. Complete Substitution Analysis of Cap18 measuring the antimicrobial activity against Aeromonas salmonicida. The
original Cap18 sequence (GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY) and amino acid assignments are presented in the
first two rows. The second column identifies the amino acid substitution at each position (A-Y). Each box in the matrix represents a
Cap18 peptide harboring one single amino acid substitution compared to the original Cap18 sequence. For example, the amino acid
sequence of the peptide in column 1/row 1 is ALRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of the peptide in
column 1/row 2 is CLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of peptide in column 2/row 1 is
GARKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY etc.; the values within each box represent a MIC value (μg/ml) against
Aeromonas salmonicida. Grey boxes represent the original Cap18 sequence. NS = no MIC value determination possible due to the
insolubility of the peptide in DMSO.
https://doi.org/10.1371/journal.pone.0197742.g001
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Similar results were found for the specific activity of Cap18 against Y. ruckeri. The hydro-
phobic positions L6, I13, L17, I20, I24 are important for the antimicrobial activity of Cap18. In
particular, substituting residue L6 by D or P, residue I13 by D, F, K, Q or S, residue I20 by D,
K, P, residue I24 by D, E, H, N or Q led to major loss of antimicrobial activity. In addition,
exchanging the charged residue K18 by P reduced the efficacy of Cap18 against Y. ruckeri by a
factor of16 (Table 4).
Against S. Typhimurium the antimicrobial activity was abolished by introducing D, F, or P
at the hydrophobic position I13; D, E, or P at position L17; or D, E, N at position I24. In addi-
tion, the Cap18 peptide harboring a L31C mutation lost the antimicrobial activity with a MIC
32. However, not only changing hydrophobic residues of Cap18 will lead to a reduced anti-
microbial activity against S. Typhimurium. Cap18 T35H and Cap18 Y37D have a MIC MIC
32, and are therefore ineffective against S. Typhimurium (Table 4). To conclude, these data
suggest that an intact hydrophobic interface of Cap18 consisting of the residues I13, L17 and
I24 is required for the antimicrobial activity of Cap18 against all the tested pathogens Y. ruck-
eri, A. salmonicida and S. Typhimurium.
Screening for Cap18 derivatives with changed species-specificity
The use of traditional antibiotics not only selects for resistance, but also disturbs and alters
the microbiota, which plays an important role in human and animal health. Therefore it
would be desirable to design AMPs with both, high antimicrobial activity and high species
selectivity. To identify and design Cap18 derivatives, which are both, highly active and
Fig 2. Complete Substitution Analysis of Cap18 measuring the antimicrobial activity against Yersinia ruckeri. The original Cap18
sequence (GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY) and amino acid assignments are presented in the first two rows.
The second column identifies the amino acid substitution at each position (A-Y). Each box in the matrix represents a Cap18 peptide
harboring one single amino acid substitution compared to the original Cap18 sequence. For example, the amino acid sequence of the
peptide in column 1/row 1 is ALRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of the peptide in column 1/row 2
is CLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of peptide in column 2/row 1 is GARKRLRKFRNKIKEKL
KKIGQKIQGLLPKLAPRTDY etc.; the values within each box represent a MIC value (μg/ml) against Yersinia ruckeri. Grey boxes
represent the original Cap18 sequence. NS = no MIC value determination possible due to the insolubility of the peptide in DMSO.
https://doi.org/10.1371/journal.pone.0197742.g002
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Fig 3. Complete substitution Analysis of Cap18 measuring the antimicrobial activity against SalmonellaTyphimurium. The
original Cap18 sequence (GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY) and amino acid assignments are presented in the
first two rows. The second column identifies the amino acid substitution at each position (A-Y). Each box in the matrix represents a
Cap18 peptide harboring one single amino acid substitution compared to the original Cap18 sequence. For example, the amino acid
sequence of the peptide in column 1/row 1 is ALRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of the peptide in
column 1/row 2 is CLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of peptide in column 2/row 1 is
GARKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY etc.; the values within each box represent a MIC value (μg/ml) against
Salmonella Typhimurium. Grey boxes represent the original Cap18 sequence. NS = no MIC value determination possible due to the
insolubility of the peptide in DMSO.
https://doi.org/10.1371/journal.pone.0197742.g003
Table 3. Overview of the antimicrobial activity of 696 Cap18 derivatives.
MIC [μg/ml]
>32 32 16 8 4 2 1–2 1 0.5–1 0.5
A. salmonicida
ATCC33658
Number of
variants
3 9 13 40 186 388 23 30 3 1
% 0.4% 1.3% 1.9% 5.7% 26.7% 55.7% 3.3% 4.3% 0.4% 0.1%
Y. ruckeri 392/2003
Number of
variants
10 13 24 52 127 375 26 62 6 1
% 1.4% 1.9% 3.4% 7.5% 18.2% 53.9% 3.7% 8.9% 0.9% 0.1%
S. Typhimurium LT2
Number of
variants
5 9 11 63 342 234 27 5 0 0
% 0.7% 1.3% 1.6% 9.1% 49.1% 33.6% 3.9% 0.7% 0% 0%
L. lactis IL1403
Number of
variants
36 11 42 177 269 145 - 14 - 2
% 5.2% 1.6% 6.0% 25.4% 38.7% 20.8% - 2% - 0.3%
Cap18 variants with unchanged MIC value compared to the original Cap18 are highlighted in grey
https://doi.org/10.1371/journal.pone.0197742.t003
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exhibit a targeted species specificity by only killing one specific target pathogen, the Cap18
library was screened for antimicrobial activity against both, pathogenic and beneficial bac-
teria. In addition to the screened pathogens Y. ruckeri, A. salmonicida and S. Typhimurium,
the Cap18 peptide library was screened for the loss of antimicrobial activity against the ben-
eficial organism Lactococcus lactis. The MIC values representing the antimicrobial activity
against L. lactis are summarized in Fig 4 and Table 3. 59.5% of the Cap18 variant peptides
had a MIC value of 2–4 μg/ml which corresponds to wild-type activity. 5.2% of the tested
Cap18 derivatives showed a MIC of 32 μg/ml which corresponds to loss of antimicrobial
activity of more than 8 fold, whereas only 2.3% were slightly more active the original Cap18
peptide (Table 3).
To identify Cap18 variant peptides with changed species specificity, the antimicrobial
screening data of Y. ruckeri, A. salmonicida, S. Typhimurium and L. lactis was compared.
Cap18 peptides with a changed antimicrobial spectrum were identified and classified into two
different groups (class I and II) according to the following selection criteria (Table 5): Class I
peptides have lost the antimicrobial activity against all the screened test strains (MIC32 μg/
ml) and class II peptides show a species specific loss of antimicrobial activity (targeted antimi-
crobial activity). More detailed, peptides from class II exhibit wild-type antimicrobial activity
(Table 2) against at least one test strain while at the same time having completely lost the anti-
microbial activity against at least another screening strain (MIC32 μg/ml). To summarize,
out of 696 tested Cap18 derivatives, 34 peptides showed a changed species specificity (Class II
peptides). Those peptides kept unchanged antimicrobial activity against at least one screening
strain, while at the same time being ineffective against at least another screening strain. Inter-
estingly, only 7 derivatives (class I) lost the antimicrobial activity completely and had no anti-
microbial effect against all the tested organisms.
Generating Cap18 peptides with engineered species specificity by
introducing one single amino acid exchange
To validate and confirm the screening results, 6 peptides from class I and 22 Cap18 peptides
from class II were ordered as highly pure peptides (purity >95%). In addition, three Cap18
derivatives harboring either a I13F, I13M or G26T substitution were ordered as positive
controls. These three derivatives showed unchanged antimicrobial activity compared to the
original Cap18 peptide in the initial screening (S1 Table). The antimicrobial activity of the
highly pure peptides was determined by measuring the MIC value of each derivative against
the four test strains Y. ruckeri, A. salmonicida, S.Typhimurium and L. lactis (Table 6). By
comparing the MIC data, Cap18 derivatives from class II with changed species-specificity
could be identified. Cap18 derivatives with a changed antimicrobial profile being ineffective
against at least one tested organism (MIC 32 μg/ml), while at the same time retained full
antimicrobial activity against another species exhibit species-specific antimicrobial activity.
All Cap18 derivatives with changed species-specificity and their antimicrobial activity pat-
tern are summarized in Fig 5. In addition to the additional screening strains, a wider range
of relevant pathogens including Gram-positive and Gram-negative bacteria was analyzed
for targeted antimicrobial activity. The MIC values were determined using highly pure pep-
tides against E. coli, P. aeruginosa, L. monocytogenes and E. faecalis and the results are sum-
marized in Table 6.
Based on all the collected MIC data using highly pure Cap18 peptides, we can conclude that
13 derivatives of Cap18 were identified with changed species-specificity by introducing one
single amino acid substitution compared to the original Cap18 peptide (Fig 5). In addition,
introducing the following substitutions I13D, L17D, L17P, I24D or I24N leads to a complete
Enhanced specificity of antimicrobial peptide Cap18
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loss in antimicrobial activity (MIC values 32 μg/ml) against all the tested bacterial species
including Gram-positive and Gram-negative bacteria. Amino acids I13, L17, and I24 of Cap18
seem to be of specific importance for general antimicrobial activity of Cap18 against both,
Gram-negative and Gram-positive bacteria. These findings are in agreement with the initial
screening data (Table 4).
Table 4. Unfavorable amino acid substitutions in Cap18 based on MIC values of Cap18 derivatives for A. salmonicida,Y. ruckeri,L. lactis and S. Typhimurium lead-
ing to a reduced antimicrobial activity.
Position Parent Amino Acid Not Favored Substitution–Reduction of Antimicrobial Activity
(MIC 32 μg/ml)
A. salmonicida Y. ruckeri S. Typhimurium L. lactis
1 G
2 L
3 R
4 K
5 R
6 L D,P R
7 R
8 K
9 F
10 R L
11 N
12 K
13 I D,F,P,R D,F,K,Q,S D,F,P D,E,F,H,K,N,P,Q,R
14 K
15 E
16 K C,F,I,L,M,Y
17 L D,P D,E,H,K,N,P,Q D,E,P C,D,E,H,K,N,P,Q
18 K P P
19 K
20 I D,K,P D,E,H,K,N,P,Q,R,
21 G C,I,L,
22 Q
23 K
24 I D,E,N,Q,R D,E,H,N,Q D,E,N, C,D,E,G,H,N,Q,R,S
25 Q
26 G
27 L P
28 L K
29 P
30 K
31 L C
32 A
33 P
34 R
35 T H
36 D
37 Y D
https://doi.org/10.1371/journal.pone.0197742.t004
Enhanced specificity of antimicrobial peptide Cap18
PLOS ONE | https://doi.org/10.1371/journal.pone.0197742 May 31, 2018 10 / 25
The proline residue at position 29 is essential for the differentiation
between prokaryotic and eukaryotic cells
Not only a high antimicrobial activity, but also the ability to differentiate between bacterial
and mammalian cells is an important characteristic for a successful antimicrobial peptide. The
cytotoxicity was determined using a hemolytic assay based on the lysis of washed horse eryth-
rocytes. The Cap18 peptide with high purity (89.5%) had at the peptide concentration of
64 μg/ml a very minimal hemolytic activity (1% compared to the triton X-100 control)
(Table 7) which is in agreement with previously published data [21]. To validate the original
Cap18 peptide from the positional scanning library, which has a lower purity of only 47.5%
purity, the hemolytic activity was determined to 2% ± 1% (32 μg/ml final peptide concentra-
tion in the assays), which was very similar to the measured hemolytic activity of the pure
Cap18 peptide (Table 7). Summarizing, both the highly pure Cap18 peptide and the library
Cap18 peptide showed minimal hemolytic activity at the measured concentrations. The sol-
vent DMSO alone had no hemolytic activity in the concentration range used in the assay (data
not shown).
To identify which residues of Cap18 play a central role in generating specificity between
eukaryotic and prokaryotic cells, the hemolytic activity of all the 696 Cap18 derivatives was
therefore determined measuring the hemoglobin release of horse erythrocytes at a peptide
concentration of 32 μg/ml (Fig 5). Out of the 696 tested Cap18 derivatives, 550 peptides
(79.1%) had no or minimal hemolytic activity similar to the original Cap18 peptide. 60 Cap18
derivatives showed an hemolytic activity of 4–5% which is a slight increase compared to the
Fig 4. Complete Substitution Analysis of Cap18 measuring the antimicrobial activity against Lactococcus lactis. The original Cap
sequence is (GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY) and amino acid assignments are presented in the first two rows.
The second column identifies the amino acid substitution at each position (A-Y). Each box in the matrix represents a Cap18 peptide
harboring one single amino acid substitution compared to the original Cap18 sequence. For example, the amino acid sequence of the
peptide in column 1/row 1 is ALRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of the peptide in column 1/row 2 is
CLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of peptide in column 2/row 1 is GARKRLRKFRNKIKEKLKKIG
QKIQGLLPKLAPRTDY etc.; the values within each box represent a MIC value (μg/ml) against Lactococcus lactis. Grey boxes represent
the original Cap18 sequence. NS = no MIC value determination possible due to the insolubility of the peptide in DMSO.
https://doi.org/10.1371/journal.pone.0197742.g004
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original Cap18 peptide. 64 derivatives displayed a hemolytic activity of 6–10% compared to
the original Cap18 peptide, 16 derivatives had a hemolytic activity of 11–15% and 6 derivatives
Table 5. Cap18 derivatives identified in the screening with lost antimicrobial activity or changed species-specificity.
Cap18 variant peptides Antimicrobial Activity–MIC in μg/ml
Amino Acid Position Peptide Class Mutation L. lactis S. Typhimurium Y. ruckeri A. salmonicida
L 6 II L6D 16 8 32 16
II L6P 8 4 32 8
II L6R 32 8 16 16
R 10 II R10L 32 4 8 4
I 13 I I13D 32 32 32 32
I I13F 32 32 32 32
II I13H 32 8 8 4
II I13N 32 8 - 8
II I13Q 32 4 32 4
II I13S 8 4 32 2
K 16 II K16C 32 8 2 4
II K16F 32 8 4 4
II K16I 32 4 4 4
II K16L 32 4 4 4
II K16M 32 4 4 4
II K16Y 32 8 8 4
L 17 II L17C 32 8 ? 8
I L17D 32 32 32 32
II L17H 32 8 32 8
II L17K 32 4 32 4
I L17P 32 32 32 32
K 18 II K18P 32 4 32 2
I 20 II I20E 32 4 16 8
II I20H 32 2 8 2
II I20N 32 4 16 4
II I20Q 32 8 8 8
II I20R 32 8 16 16
G 21 II G21C 32 8 4 4
II G21I 32 8 8 8
II G21L 32 8 4 4
I 24 II I24C 32 4 4 4
I I24D 32 32 32 32
I I24E 32 32 32 32
II I24G 32 4 16 8
II I24H 32 8 32 8
I I24N 32 32 32 32
II I24S 32 4 16 8
L 27 II L27P 32 4 16 16
L 31 II L31C 8 32 4 4
T 35 II T35H 8 32 2 2
Y 37 II Y37D 8 32 2 2
Class I peptides are highlighted in light grey and class II peptides are shown in dark grey. Cap18 variant peptides chosen for further analysis using pure peptides (purity
>95%) are marked with .
https://doi.org/10.1371/journal.pone.0197742.t005
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exhibited a hemolytic activity of16% (Fig 6, Table 8). Exchanging proline 29 by any other
amino acid led to increased hemolytic activity compared to the non-hemolytic Cap18 original
peptide. Substituting residues K16, G21 and K23 by any hydrophobic amino acid (A, F, I, L, M
V or W) raises the hemolytic activity of the derivatives compared to the original Cap18 pep-
tide. In addition, substituting negatively charged residues at position R5, R10, K12, K4, K16,
K23, K30 and R34 leads to higher hemolytic activity (Fig 6, Table 8). To validate the screening
data, the hemolytic activity of the pure Cap18 derivatives Peptide 1–31 which were previously
selected based on changed antimicrobial activity pattern (Table 6), was determined. In
Table 6. Antimicrobial activity of purified Cap18 derivatives against Gram-negative and Gram-positive bacteria.
Antimicrobial Activity [μg/ml]
Gram-negative bacteria Gram-positive bacteria
Cap18 peptides Substitution S. Typhimurium
LT2
Y. ruckeri
392/2003
A. salmonicida
ATCC33658
E. coli
ATCC25922
P. aeruginosa
ATCC27853
L. lactis
IL1403
L. monocytogenes
N22-2
E. faecalis
ATCC29212
Cap18—pure Original sequence 4–8 2–4 4 4–8 4–8 1–2 4 8
Peptide 1 L6P 8 64 8–16 8 64 64 32 32
Peptide 2 R10L 16 32 32 32 32 64 8–16 16–32
Peptide 3 I13D 64 64 64 64 64 64 32–64 64
Peptide 4 I13F 4 2 4 4–8 4–8 2 4 8–16
Peptide 5 I13H 4 8–16 2–4 4 8–16 64 32 64
Peptide 6 I13M 8 4 4 8–16 8–16 2 4 8–16
Peptide 7 I13Q 4–8 8 8 16–32 8 64 16 32
Peptide 8 I13S 8 8–16 4 16 8–16 64 32 64
Peptide 9 K16C 8–16 8–16 8 8 16–32 64 16 32
Peptide 10 K16D 4 4 2–4 4–8 16–32 2 4–8 32
Peptide 11 K16F 16 16–32 16–32 16 32 64 16 16
Peptide 12 K16I 16 16 8–16 16 16 64 8–16 16
Peptide 13 K16L 16 16 16 16 16–32 64 8–16 16
Peptide 14 K16M 16 8–16 8–16 16 16–32 64 16 32
Peptide 15 K16Y 16 8–16 16 16 16 64 8–16 16
Peptide 16 L17D 64 64 64 64 64 64 64 64
Peptide 17 L17K 16 64 16–32 64 8 64 16–32 64
Peptide 18 L17P 64 64 64 64 64 64 64 64
Peptide 19 K18P 4 32 2–4 8–16 16 32 32–64 64
Peptide 20 I20E 8 32 16 64 16 32 32 64
Peptide 21 I20H 8 16 4 32 8 32 16 64
Peptide 22 I20N 8–16 64 16 64 8–16 64 16–32 64
Peptide 23 G21C 16 16 16–32 16 32 64 16 32
Peptide 24 G21L 16 16 16 16 16 64 16 16
Peptide 25 I24C 8–16 16 4–8 16 16 64 16 64
Peptide 26 I24D 64 64 64 64 64 64 64 64
Peptide 27 I24G 8–16 32 8 64 16 64 32 64
Peptide 28 I24N 32 64 64 64 64/16 64 32 64
Peptide 29 I24S 8 16 8 32–64 8–16 32 16–32 64
Peptide 30 G26T 4–8 2–4 4 4–8 8 2 4 8
Peptide 31 L27P 8 32 16 64 8 32 32 64
Data are collected as minimal inhibitory concentrations (MICs) according to the Clinical and Laboratory Standards Institute (CLSI) and expressed in μg/ml. All MIC
determinations were carried out in triplicate. MIC values are given as a single value when replicates gave identical results whereas two values are given when replicates
differed by one well.
https://doi.org/10.1371/journal.pone.0197742.t006
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addition, five Cap18 derivatives harboring a substitution at P29 were ordered as peptides with
high purity (Peptide 32–36) and the hemolytic activity was determined. Results of the hemo-
lytic assay are presented in Table 7. In summary, the screening data and the dataset using puri-
fied peptides provide evidence that residue P29, K16, G21 and L23 plays the central role in the
hemolytic activity of Cap18 and are involved in generating specificity between eukaryotic and
prokaryotic cells.
Discussion
The number of antimicrobials entering the market is significantly decreasing since the golden
age of the antibiotic discovery in the mid-1900s and simultaneously, the levels of antimicrobial
resistance amongst bacterial pathogens are rising which calls for alternative solutions control-
ling bacterial infections [27]. The majority of the currently used antimicrobials have a broad
killing spectrum. This has the advantage that they can be used without precise diagnosis, but
they also disrupt the normal microbiota by killing the beneficial commensal bacteria which
can lead to severe side-effects. Antimicrobial peptides are an attractive alternative to create
novel, target-specific antimicrobials. The aim of this study was to design and identify antimi-
crobial peptides with greater specificity and more targeted antimicrobial activity based on the
cathelicidin Cap18, a cationic AMP originally isolated from rabbit neutrophils.
Combinatorial libraries, prepared through chemical synthesis, or biological libraries such as
phage display, represent powerful tools to optimize existing antimicrobial peptides [28]. By
designing and screening a positional scanning library of Cap18, we successfully designed
Cap18 peptide derivatives with changed species specificity and the potential to be used in tar-
get-specific antimicrobial therapy by introducing single amino acid substitutions in the origi-
nal Cap18 sequence. Generally, by screening the positional scanning library of Cap18, we were
able to analyze the antimicrobial and hemolytic properties of Cap18 and to identify specific
residues within the amino acid sequence of Cap18 which are crucial for antimicrobial activity
and required for the inherent low hemolytic activity of Cap18. Peptide libraries are a powerful
tool to optimize the properties of antimicrobial peptides. However, the quality and purity of
the peptides is important for the subsequent screening applications and the accuracy of the
obtained results. Since we used a peptide library consisting of crude purity peptides, positive
hits identified in the screening needed further confirmation and verification using purified
peptides (purity95%). Comparing the MIC values recorded for crude and highly pure pep-
tides, we can suggest that the quality of a crude peptide library allows the discrimination
between active and non-active Cap18 derivatives. More subtle changes in the antimicrobial
activity are difficult to measure using crude peptides due to impurities even after adjusting for
the different purities of the individual Cap18 derivatives. The impurities in the crude peptides
of low yield are likely to be peptides of related sequences with premature termination or other
Fig 5. Cap18 derivatives with changed species-specificity. Unchanged antimicrobial activity compared to the
original Cap18 is indicated by +, whereas the loss of antimicrobial activity (MIC32 μg/ml) is illustrated by -. Gram-
negative bacteria are highlighted in light blue, Gram-positive bacteria are presented in light brown.
https://doi.org/10.1371/journal.pone.0197742.g005
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mistakes in the synthesis. Such peptides might have similar antimicrobial activity to the pep-
tide of desired sequence and if considered as a mere diluent the antimicrobial activity might be
overestimated. Crude peptide libraries will therefore be more efficient in detecting loss of func-
tion than in detecting modest increase in activity In order to be able to measure smaller
changes in the antimicrobial activity, peptide libraries with high purity are needed. This might
only be applicable and a valid alternative for shorter peptides due to the high synthesis costs.
Table 7. Unfavorable amino acid substitutions of Cap18 leading to increased hemolytic activity against horse
erythrocytes.
Position Parent Amino Acid Hemolytic activity
6% -10% 11%-15% 16%
1 G
2 L I
3 R
4 K
5 R W
6 L
7 R
8 K
9 F
10 R F,L,W
11 N
12 K W
13 I
14 K W
15 E
16 K A,C,F,I,L,M,V,W S
17 L I
18 K A,H Q,Y
19 K G
20 I
21 G F,L,Y W
22 Q K S
23 K A,I,N,V,W,Y C,F,L,M
24 I
25 Q C,I,L,V,W,Y F
26 G E,W L,R
27 L C,I
28 L F,H M
29 P E,F,H,I,K,L,M,N,R,V,W C D
30 K C,Q,W Y
31 L
32 A F,I C
33 P W
34 R K,R
35 T I C
36 D C,W,Y F
37 Y I,M,Q
https://doi.org/10.1371/journal.pone.0197742.t007
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Physiochemical and structural parameters such as hydrophobicity, cationicity, amphipathi-
city and amino acid composition are important determinants for the antimicrobial activity of
α-helical AMPs (reviewed [13]). By screening the positional scanning library of Cap18, fol-
lowed by the validation of potential hits using peptides with high purity, specific residues
within the Cap18 amino acid sequence were identified which are strictly required for antimi-
crobial activity against Gram-positive as well as Gram-negative bacteria. Peptides 3, 16, 18, 26
and 28 harboring either a I13D, L17D, L17P, I24D or I24N substitution lost their antimicrobial
activity and are completely ineffective against all tested bacterial species. Residues I13, L17 and
I24 are all part of the hydrophobic face highlighted in the predicted structure or illustrated by
the helical wheel projection of Cap18 (Figs 7 and 8). The introduction of non-hydrophobic
amino acids in particular the negatively charged residue D at position 13, 17 or 24 will disrupt
the hydrophobic interface (Fig 8). The disruption of the hydrophobic patch will most likely
prevent optimal interaction with the bacterial membrane and therefore interfere with the
insertion of the peptide in to the lipid bilayer. This reduced antimicrobial efficacy of peptides
3, 16, 18, 26 and 28 nicely correlates with a reduction in the mean hydrophobicity <H> and
the mean hydrophobic moment <μH> calculated by HeliQuest (http://heliquest.ipmc.cnrs.
fr). The mean hydrophobic moment <μH> is a measure of the amphiphilicity of the α-helix,
in which the length and direction of the<μH> vector are depending on the hydrophobicity
and the position of the side chains along the helix axis. Large <μH> value implies that the
helix is amphipathic perpendicular to its axis [29]. Apart from peptides 3, 16, 18, 26 and 28,
additional derivatives with substitutions at positions 13, 17 or 24 displayed a changed antimi-
crobial activity pattern. In contrast to peptides 3, 16, 18, 26 and 28, peptides 5, 7 and 8
Fig 6. Complete Substitution Analysis of Cap18 measuring the hemolytic activity of Cap18 peptides against horse erythrocytes.
The original Cap18 sequence (GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY) and amino acid assignments are presented in
the first two rows. The second column identifies the amino acid substitution at each position (A-Y). Each box in the matrix represents
a Cap18 peptide harboring one single amino acid substitution compared to the original Cap18 sequence. For example, the amino acid
sequence of the peptide in column 1/row 1 is ALRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of the peptide in
column 1/row 2 is CLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of peptide in column 2/row 1 is
GARKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY etc.; the values within each box represent the hemolytic activity measured
relative to full lysis by 0.2% Trition X-100. The final peptide concentration in the assay is 32 μg/ml. Grey boxes with X represent the
original Cap18 sequence. NS = no MIC value determination possible due to the insolubility of the peptide in DMSO.
https://doi.org/10.1371/journal.pone.0197742.g006
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retained full antimicrobial activity against some bacterial species and at the same time became
ineffective against other bacteria. Those variants are acting in a species-specific manner com-
pared to the original Cap18 peptide having a broad antimicrobial activity. In more detail,
Table 8. Hemolytic activity against horse erythrocytes, calculated hydrophobicity, hydrophobic moment and net charge of Cap18 and Cap18 derivatives.
Peptide Substitution Peptide concentration [μg/ml] Haemolytic Activity [%] Hydrophobicity <H> Hydrophobic Moment <μH> Net Charge
Cap18 –pure1) original 64 1% ± 1% 0.107 0.471 +12
Cap18 –library2) original 32 2% ± 1% 0.107 0.471 +12
Peptide 1 L6P 64 1% 0.080 0.445 +12
Peptide 2 R10L 64 6% 0.180 0.518 +11
Peptide 3 I13D 64 1% 0.037 0.402 +11
Peptide 4 I13F 64 2% 0.106 0.471 +12
Peptide 5 I13H 64 1% 0.062 0.426 +12
Peptide 6 I13M 64 2% 0.091 0.456 +12
Peptide 7 I13Q 64 1% 0.052 0.417 +12
Peptide 8 I13S 64 1% 0.057 0.421 +12
Peptide 9 K16C 64 4% 0.175 0.502 +11
Peptide 10 K16D 64 1% 0.113 0.473 +10
Peptide 11 K16F 64 9% 0.182 0.505 +11
Peptide 12 K16I 64 10% 0.182 0.505 +11
Peptide 13 K16L 64 14% 0.179 0.504 +11
Peptide 14 K16M 64 8% 0.167 0.497 +11
Peptide 15 K16Y 64 9% 0.159 0.494 +11
Peptide 16 L17D 64 0% 0.040 0.417 +11
Peptide 17 L17K 64 1% 0.034 0.412 +13
Peptide 18 L17P 64 0% 0.080 0.449 +12
Peptide 19 K18P 64 1% 0.153 0.441 +11
Peptide 20 I20E 64 1% 0.041 0.413 +11
Peptide 21 I20H 64 1% 0.062 0.431 +12
Peptide 22 I20N 64 0% 0.042 0.414 +12
Peptide 23 G21C 64 4% 0.148 0.485 +12
Peptide 24 G21L 64 7% 0.153 0.486 +12
Peptide 25 I24C 64 2% 0.100 0.464 +12
Peptide 26 I24D 64 0% 0.037 0.403 +11
Peptide 27 I24G 64 1% 0.058 0.424 +12
Peptide 28 I24N 64 1% 0.042 0.408 +12
Peptide 29 I24S 64 1% 0.057 0.423 +12
Peptide 30 G26T 64 2% 0.114 0.465 +12
Peptide 31 L27P 64 1% 0.080 0.453 +12
Peptide 32 P29A 64 4% 0.096 0.481 +12
Peptide 33 P29D 64 3% 0.066 0.507 +11
Peptide 34 P29F 64 7% 0.136 0.445 +12
Peptide 35 P29H 64 3% 0.091 0.485 +12
Peptide 36 P29S 64 4% 0.086 0.489 +12
1) Purity89.5%
2) Purity 47.5%
The hemolytic activity is measured in duplicates and given as the average ± SD in % relative to full lysis by 0.2% triton X-100. Mean hydrophobicity <H>, hydrophobic
moment <μH>, and net charge are calculated using heliquest (http://heliquest.ipmc.cnrs.fr).
https://doi.org/10.1371/journal.pone.0197742.t008
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Peptide 5 harboring a I13H substitution retained full antimicrobial activity against S. Typhi-
murium LT2, reduced activity against the other Gram-negative bacteria tested and completely
lost efficacy against the three tested Gram-positive species. Similarly, peptides 7 and 8 showed
changed species-specificity. Peptide 7 (I13Q) was completely ineffective against L. lactis, how-
ever fully active against S. Typhimurium LT2 and P. aeruginosa ATCC27853, whereas peptide
8 (I13S) was active against S. Typhimurium LT2 and A. salmonicida ATCC33658 and ineffec-
tive against all three Gram-positive species tested. Even though the values of the calculated
hydrophobicity and hydrophobic moment are lower for peptides 5, 7 and 8 compared to the
original Cap18 peptides, peptides 5, 7 and 8 retained full antimicrobial activity against some
selected species. In addition, selected substitutions at the hydrophobic residues L6, I20 and
L27, all part of the hydrophobic face highlighted in predicted structure and illustrated by the
helical wheel projection, exhibit a changed antimicrobial activity spectrum (Fig 5). The calcu-
lated hydrophobicity and hydrophobic moment values of those derivatives, peptide 2 (L6P),
peptide 20 (I20E), peptide 21 (I20H) and peptide 31 (I27P), are lowered compared to the origi-
nal Cap18 peptide. Summarizing, we suggest that the hydrophobic residues in the hydrophobic
face might be promising targets to change the antimicrobial activity spectrum of Cap18 and to
generate Cap18 derivatives which are killing in species-specific manner. However, our data
also suggest that not only residues in the hydrophobic face might be targets for the generation
of species-specificity. Peptides 9 and 10 have cysteine or aspartic acid substitution at position
K16, which is part of the hydrophilic side of Cap18, highlighted in the structure and helical
wheel projection (Figs 7 and 8). In contrast to the derivatives having substitutions in the
hydrophobic face, peptides 9 (K16C) and 10 (K16D) are more hydrophobic than the original
Cap18 peptide displaying an increased hydrophobicity and hydrophobic moment. Based on
our results, we argue that there exists an optimal hydrophobicity of Cap18 depending on the
target organisms. A threshold hydrophobicity at which optimal antimicrobial activity can be
obtained is highly dependent on the target organism. Fine-tuning of the hydrophobicity and
hydrophobic moment of Cap18 might be a promising possibility to adjust the antimicrobial
activity dependent on the target organism and to generate Cap18 derivatives with a very nar-
row killing spectrum.
However, hydrophobicity and amphipathicity are not the only parameters determining the
antimicrobial activity of the individual Cap18 derivatives. Even though e.g. peptide 18 (L17P)
is less hydrophobic than peptide 17 (L17K) based on the calculations of<H> and<μH>,
peptide 18 has completely lost its antimicrobial activity being ineffective against all the tested
strains, whereas peptide 17 retained full antimicrobial activity against P. aeruginosa. A reduced
hydrophobicity or hydrophobic moment value alone are not sufficient to abolish the antimi-
crobial activity of Cap18 arguing that the amino acid composition plays an important role.
Proline is a well-known helix-breaker causing a kink in the helix. This is caused by proline
being unable to complete the H-bonding chain and by steric effects preventing proline from
adapting the preferred helical geometry [33]. Glycine has poor helix forming properties and
tends to disrupt α-helices due to its high conformational flexibility. Therefore, the presence of
glycine and proline could have a critical effect on the antimicrobial and hemolytic activity of
α-helical AMPs. Proline residues are often found within the amphipathic a-helix of AMPs and
therefore the importance of proline residues in AMPs has been investigated. Previous studies
investigating the effect of proline on the biological activity of α-helical AMPs revealed that sub-
stitution of proline decreased the antimicrobial activity. Substitution of the central proline by
alanine in gaegurin [34] or by leucine or alanine in the hybrid analog P18 resulted in a reduc-
tion of antimicrobial activity [35]. Further, it was shown that the proline hinge in buforin II is
responsible for its cell-penetrating ability [36] and the central PXXP hinge of PMAP-23 is
important for its antimicrobial activity [37]. Our data on Cap18 shows that the introduction of
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proline at specific sites of Cap18 changes the antimicrobial activity as well as the species-speci-
ficity depending on the site of introduction. Replacing the central leucine at position 17 by a
proline causes a complete loss of antimicrobial activity (peptide 18). This finding is in agree-
ment with previous studies which showed that the introduction of proline in α-helical AMPs
decreased the ability of the peptide to penetrate the cytoplasmic membrane of E. coli which
was concomitant with a reduction in the antimicrobial activity [38,39]. However, introducing
a proline residue at position L6, K18 or L27 does not abolish antimicrobial activity completely,
but generates Cap18 derivatives with a changed antimicrobial activity spectrum. The antimi-
crobial activity pattern of peptide 1, peptide 19 and peptide 31, all harboring a proline inser-
tion, are different depending on the target species as well as on the insertion site of the proline
residue. All three derivatives kept unchanged antimicrobial activity against S. Typhimurium
LT2, whereas all three were completely ineffective against Y. ruckeri, L. lactis and L. monocyto-
genes. Analyzing the remaining results of those three derivatives harboring a proline insertion,
we can argue that the antimicrobial activity depends on both the position of proline insertion
and the target organism itself (Table 5). Summarizing, we can suggest that the dramatic effect
of introducing a proline at residue L17 resulting in complete loss of antimicrobial activity
might be due to a structural change in the helix preventing optimal interaction with the mem-
brane which is crucial for antimicrobial activity of Cap18. However, the positioning of proline
residues determines how the antimicrobial activity is affected–positively or negatively
Fig 7. Predicted structure of Cap18. The structure of Cap18 was predicted using I-Tasser [30] and visualized by
CCP4 software [31]. The predicted α-helix is highlighted in red. Hydrophobic residues of the α-helix are shown in
green. Specific residues are highlighted the following: K16, K18 and K23 in blue and P29 in black. A: view along helix
axis B: view from N- to C-terminal C: view form C- to N-terminal.
https://doi.org/10.1371/journal.pone.0197742.g007
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depending on the target organism. This is in agreement with a previous study demonstrating
that the properties conferred on AMPs by proline residues strongly depends on the properties
of the proline-free template peptide as well as the positioning of the proline residue in the pri-
mary sequence [40].
Fig 8. Helical wheel projection of the original Cap18 peptide and Cap18 derivatives. Hydrophobic amino acids are
yellow, negatively charged amino acids are red and positively charged amino acids are in dark blue. Particular polar
residues are violet (threonine, serine) or pink (asparagine, glutamine). Glycine and alanine are grey and proline
residues are shown in green. The helices were created using http://heliquest.ipmc.cnrs.fr/ [32]. A: helical wheel
projection of the original Cap18 peptide. Residues important for the hemolytic activity and antimicrobial activity of
Cap18 are highlighted. B-E: helical wheel projections of Cap18 derivatives that lost the antimicrobial activity against all
the tested organisms. Peptide 3 harboring the I13D amino acid substitution (B), Peptide 16 harboring the L17D
substitution (C), Peptide 18 harboring the L17P substitution (D) and Peptide 26 harboring the I24D substitution (E).
Corresponding substitutions are highlighted.
https://doi.org/10.1371/journal.pone.0197742.g008
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Apart from high antimicrobial activity, low cytotoxicity is a very desirable characteristic for
antimicrobial peptides used as potential drug candidates. The original Cap18 peptide displays
low hemolytic activity in vitro measuring the hemoglobin release of horse and trout erythro-
cytes [22][21]. In order to design AMPs with optimized characteristics for potential therapeu-
tic use, it is crucial to understand how cell selectivity is generated and which residues are
responsible for the inherent low hemolytic activity of Cap18. Analysis of the screening data
investigating the hemolytic effect of Cap18 derivatives reveals a crucial role of proline at posi-
tion 29 for the differentiation between mammalian and bacterial membrane. Substituting P29
by any other amino acid will lead to increased hemolytic activity concluding that the presence
of P29 in the original Cap18 is crucial for its inherent low hemolytic activity. Looking at the
predicted structure of Cap18, P29 is situated at the very end of the predicted a-helix. The pres-
ence of proline residues in AMPs which might cause kinks in the α-helix, not only affects the
antimicrobial activity, but also the hemolytic activity. Previous studies have found that the
elimination of proline at position 7 in the α-helical pardaxin, substituting proline at position
14 in melittin by alanine or replacing the glycine residues at position 13 or 17 in pleurocidin
are resulting in increased hemolytic activity[41–43]. Similarly, incorporating a proline kink in
the α-helical AMP Anal 3 by replacing glutamic acid by proline in the middle of the peptide
sequence had positive effect on hemolytic activity showing reduced membrane damaging
activity of Anal 3-Pro compared to the original Anal 3 peptide [44]. Introducing a proline resi-
due at any other position of Cap18 has no negative effect on the hemolytic activity. Interest-
ingly, the substitution of P29 had no or only very minor effect on the antimicrobial activity
regardless of the target organism. This suggests that P29 is crucial for the specificity between
prokaryotes and eukaryotes and plays a minor role for the antimicrobial activity of Cap18.
Hydrophobicity (H), hydrophobic moment (μH) and net charge are important physiochemical
parameters controlling cell selectivity. The initial screening shows that the substitution of the
positive charged residues K16 and K23 as well as G21 by any hydrophobic residues (not pro-
line) enhance the hemolytic activity (Fig 6, Table 7). K16, G21, and K23 all being part of the
hydrophilic interface are situated right next to the hydrophobic face which illustrated by the
helical wheel projection (Fig 8). Peptide 23 and peptide 24 harboring a G21C or G21L substi-
tution are more hydrophobic and more hemolytic active compared to the original Cap18 pep-
tide. Similarly, replacing K16 with hydrophobic amino acids (peptide 9, peptide 11, peptide
12, peptide 13, peptide 14 and peptide 15) leads to a higher mean hydrophobicity and hydro-
phobic moment than the original Cap18 peptide which is consistent with enhanced hemolytic
activity (Fig 8). Concluding, we can suggest that enhanced hemolytic activity is correlated with
increased hydrophobicity which is in agreement with previous studies [45,46]. In addition,
position K16, G21, K23 and P29 play a crucial role in generating selectivity between mamma-
lian and bacterial cells. In particular, the absence of P29 negatively affects the hemolytic activ-
ity, there is no or minor effects on the antimicrobial activity and therefore crucial for the
selectivity. In contrast, position K16 is not only important for the selectivity between bacterial
and mammalian cells, but also for the selectivity between different bacterial species. Peptide 9
(K16C) not only exhibit increased hemolytic activity, but also a changed antimicrobial activity
pattern (Fig 5). In contrast, Peptide 10 displays a changed antimicrobial activity pattern,
whereas the hemolytic activity is unchanged compared to the original Cap18 peptide. This
argues that the substitution K16D only contributes to the specificity between different bacterial
strains, but not to a more general specificity distinguishing mammalian and bacterial cells in
general.
Based on a very thorough dissection of Cap18 analyzing 696 derivatives of Cap18, we can
conclude that specific single amino acid substitution of Cap18 can alter the antimicrobial
activity pattern. We were able to generate Cap18 derivatives with target-specific activity. So
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far, only Cap18 derivatives harboring single amino acid substitutions were analyzed, however,
it would be highly interesting to see if further improvement can be achieved by combining sin-
gle substitutions and to generate derivatives with double or triple substitutions. By screening
further organisms and careful analysis of the results, as well determining the structure of
selected derivatives investigating the mode of action, it might be possible to predict Cap18
derivatives with targeted activity against any organism. However, it might be challenging to hit
the optimal window which is a delicate balance between maximum antimicrobial activity and
minimum toxicity to the host cells.
Supporting information
S1 Fig. Positional scanning library of Cap18. The original Cap18 sequence is (GLRKRLRKF
RNKIKEKLKKIGQKIQGLLPKLAPRTDY) is presented in the first row. The second column
identifies the amino acid substitution at each position (A-Y). Each box in the matrix represents
a Cap18 derivative harboring one single amino acid substitution compared to the original
Cap18 sequence. For example, the amino acid sequence of the peptide in column 1/row 1 is
ALRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of the peptide in column
1/row 2 is CLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY, the sequence of peptide in
column 2/row 1 is GARKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY.
(TIF)
S1 Table. Antimicrobial peptides used in this study.
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